AHNAK2 is a Novel Prognostic Marker and Oncogenic Protein for Clear Cell Renal Cell Carcinoma

Integrative database analysis was performed to identify novel candidate oncogene AHNAK2 overexpressed in clear cell renal cell carcinoma (ccRCC). However, the function of AHNAK2 in cancer cells is currently unknown. In this study, we first confirmed the upregulation of AHNAK2 in ccRCC tissues compared with adjacent normal tissues in 15 pairs of samples. Then we analyzed AHNAK2 expression in a large cohort of ccRCC patient samples (n = 355), and found that up-regulation of AHNAK2 was positively correlated with tumor progression and poor survival (p = 0.032). Knockdown of AHNAK2 inhibited cancer cell proliferation, colony formation and migration in vitro and tumorigenic ability in vivo. Meanwhile, knockdown of AHNAK2 impaired the cell oncologic-metabolism by inhibiting lipid synthesis. Moreover, we observed that expression of AHNAK2 was greatly upregulated, at least in part, by hypoxia in cancer cells. By using chromatin immune-precipitation (CHIP) and promoter-luciferase reporter assays, we identified that upregulation of AHNAK2 induced by hypoxia was hypoxia-inducible factor-1α (HIF1α)-dependent. Knockdown of AHNAK2 impaired hypoxia-induced epithelial-mesenchymal transition (EMT) and stem cell-like properties. Considered together, we reveal that AHNAK2 is upregulated in cancer cells and hypoxic upregulation of AHNAK2 can drive tumorigenesis and progression by supporting EMT and cancer cell stemness. Thus, AHNAK2 is a novel prognostic marker and an oncogenic protein for ccRCC.

[1]  Brian Keith,et al.  Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. , 2003, Molecular and cellular biology.

[2]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[3]  N. Gerry,et al.  Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data , 2003, BMC Cancer.

[4]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[6]  D. Stokoe,et al.  Protein kinase B phosphorylates AHNAK and regulates its subcellular localization , 2001, The Journal of cell biology.

[7]  Arianna Di Napoli,et al.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. , 2009, Cancer research.

[8]  Marie Joseph,et al.  Gene Signatures of Progression and Metastasis in Renal Cell Cancer , 2005, Clinical Cancer Research.

[9]  H. Moch,et al.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. , 2016, European urology.

[10]  S. Störkel,et al.  Ultrastructural appearance and cytoskeletal architecture of the clear, chromophilic, and chromophobe types of human renal cell carcinoma in vitro. , 1993, The American journal of pathology.

[11]  C. Delphin,et al.  Specific AHNAK expression in brain endothelial cells with barrier properties , 2005, Journal of cellular physiology.

[12]  J. Garin,et al.  AHNAK interaction with the annexin 2/S100A10 complex regulates cell membrane cytoarchitecture , 2004, The Journal of cell biology.

[13]  R. Kraft,et al.  Signaling from β‐adrenoceptor to L‐type calcium channel: identification of a novel cardiac protein kinase A target possessing similarities to AHNAK , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  G. Semenza,et al.  Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor , 2005 .

[15]  B. Loos,et al.  AHNAK: the giant jack of all trades. , 2014, Cellular Signalling.

[16]  M. Mimeault,et al.  Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells , 2013, Journal of cellular and molecular medicine.

[17]  J. Schalken,et al.  Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. , 2004, Oncogene.

[18]  N. Vogelzang,et al.  Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era , 2013, PloS one.

[19]  T. Choueiri,et al.  Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria , 2013, Cancer.

[20]  M. Scorsetti,et al.  Expression of the Transcription Factor HEY1 in Glioblastoma: A Preliminary Clinical Study , 2010, Tumori.

[21]  R. Flavell,et al.  The AHNAKs are a class of giant propeller-like proteins that associate with calcium channel proteins of cardiomyocytes and other cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Paul C. Boutros,et al.  Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER , 2014, Nature Communications.

[23]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[24]  W. Oyen,et al.  Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. , 2010, European urology.

[25]  G. Semenza,et al.  Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. , 2005, Cancer research.

[26]  Mala Sinha,et al.  Secreted Frizzled-Related Protein 1 Loss Contributes to Tumor Phenotype of Clear Cell Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[27]  B. Rini.  Targeted therapy for patients with renal-cell carcinoma. , 2011, The Lancet. Oncology.

[28]  S. Manna,et al.  Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. , 2008, The Journal of clinical investigation.

[29]  F. Kiessling,et al.  Theranostics: Methods and Protocols , 2019, Methods in Molecular Biology.

[30]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[31]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[32]  C. Kieda,et al.  The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis , 2015, Stem Cell Reviews and Reports.

[33]  A. Poprach,et al.  Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis. , 2016, European urology.

[34]  Brian Keith,et al.  Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.

[35]  R. Hill,et al.  Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. , 2013, Cancer letters.

[36]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[37]  L. Truong,et al.  Kidney-specific cadherin, a specific marker for the distal portion of the nephron and related renal neoplasms , 2005, Modern Pathology.

[38]  D. Noh,et al.  Ahnak functions as a tumor suppressor via modulation of TGFβ/Smad signaling pathway , 2014, Oncogene.

[39]  D. Shang,et al.  TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. , 2012, Urology.

[40]  Antonio Lopez-Beltran,et al.  Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. , 2015, European urology.

[41]  J. Swinnen,et al.  ATP-citrate lyase: a key player in cancer metabolism. , 2012, Cancer research.

[42]  B. Conley,et al.  AHNAK2 Participates in the Stress‐Induced Nonclassical FGF1 Secretion Pathway , 2015, Journal of cellular biochemistry.

[43]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.

[44]  M. Gordon.  Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma , 2008 .

[45]  A. Moustakas,et al.  The Notch and TGF-β Signaling Pathways Contribute to the Aggressiveness of Clear Cell Renal Cell Carcinoma , 2011, PloS one.